Publication date: Jul 28, 2025
Long COVID comprises a multisystem syndrome occurring after COVID-19. This retrospective cohort study investigated whether remdesivir given during acute COVID-19 is associated with reduced incidence of Long COVID, including in immunocompromised subgroups. The HealthVerity database of hospital chargemaster data linked to closed claims was queried for patients aged ≥ 12 years hospitalized for ≥ 2 days with COVID-19 between May 1, 2020, and September 30, 2021. Relative risk between remdesivir-exposed and unexposed patients was calculated for 16 individual Long COVID outcomes and a composite of any Long COVID outcome, occurring 90-270 days after hospital admission. Subgroup analyses occurred in immunocompromised patients. Regression models accounted for censoring, competing risks, and treatment assignment weights; statistical inferences were adjusted for multiple comparisons. Among 3,661,303 hospitalized patients, 52,006 with COVID-19 were included; 20,246 (38. 9%) were immunocompromised. In the overall and immunocompromised populations, respectively, 33. 0% and 29. 5% received remdesivir; the composite of ≥ 1 Long COVID outcome occurred in 55. 5% and 62. 9%. Patients administered remdesivir experienced lower risk of any Long COVID outcome (risk ratio, 0. 96; 95% CI 0. 94-0. 97; adjusted P
Open Access PDF
| Concepts | Keywords |
|---|---|
| Closed | Antiviral therapy |
| Immunocompromised | COVID-19 |
| Models | Immunocompromising conditions |
| Long COVID | |
| Remdesivir |
Semantics
| Type | Source | Name |
|---|---|---|
| disease | MESH | Long COVID |
| disease | MESH | COVID-19 |
| disease | MESH | syndrome |
| disease | MESH | immunocompromised patients |